{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:56:08Z","timestamp":1774994168494,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,11]]},"DOI":"10.1093\/jac\/44.5.621","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:24:55Z","timestamp":1027722295000},"page":"621-627","source":"Crossref","is-referenced-by-count":33,"title":["Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin"],"prefix":"10.1093","volume":"44","author":[{"given":"Alice","family":"Pong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S.","family":"Moland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Chartrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine C.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1999,11]]},"reference":[{"key":"key\n\t\t\t\t20170411034239_R1","doi-asserted-by":"crossref","unstructured":"Dalhoff, A. (1994). Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection22, Suppl 2, S111\u201321.","DOI":"10.1007\/BF01793575"},{"key":"key\n\t\t\t\t20170411034239_R2","doi-asserted-by":"crossref","unstructured":"Wiedemann, B. & Heisig, P. (1994). Mechanisms of quinolone resistance. Infection22, Suppl. 2, S73\u20139.","DOI":"10.1007\/BF01793570"},{"key":"key\n\t\t\t\t20170411034239_R3","doi-asserted-by":"crossref","unstructured":"Akaniro, J. C., Stutman, H. R., Arguedas, A. G. & Vargas, O. M. (1992). In-vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. Antimicrobial Agents and Chemotherapy36,255\u2013 61.","DOI":"10.1128\/AAC.36.2.255"},{"key":"key\n\t\t\t\t20170411034239_R4","doi-asserted-by":"crossref","unstructured":"Aldridge, K. E., Jones, R. N., Barry, A. L. & Gelfand, M. S. (1992). In-vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains. Diagnostic Microbiology and Infectious Disease15,517\u2013 21.","DOI":"10.1016\/0732-8893(92)90101-X"},{"key":"key\n\t\t\t\t20170411034239_R5","doi-asserted-by":"crossref","unstructured":"Thomson, K. S., Sanders, C. C. & Hayden, M. E. (1991). In-vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrobial Agents and Chemotherapy35,2329\u2013 34.","DOI":"10.1128\/AAC.35.11.2329"},{"key":"key\n\t\t\t\t20170411034239_R6","unstructured":"Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy40,639\u2013 51 (Erratum 41, 672)."},{"key":"key\n\t\t\t\t20170411034239_R7","doi-asserted-by":"crossref","unstructured":"Brueggemann, A. B., Kugler, K. C. & Doern, G. V. (1997). In-vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy41,1594\u2013 7.","DOI":"10.1128\/AAC.41.7.1594"},{"key":"key\n\t\t\t\t20170411034239_R8","doi-asserted-by":"crossref","unstructured":"Dalhoff, A., Petersen, U. & Endermann, R. (1996). In-vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy42, 410\u201325.","DOI":"10.1159\/000239474"},{"key":"key\n\t\t\t\t20170411034239_R9","doi-asserted-by":"crossref","unstructured":"Fass, R. J. (1997). In-vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrobial Agents and Chemotherapy41,1818\u2013 24.","DOI":"10.1128\/AAC.41.8.1818"},{"key":"key\n\t\t\t\t20170411034239_R10","doi-asserted-by":"crossref","unstructured":"Souli, M., Wennersten, C. B. & Eliopoulos, G. M. (1998). In-vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. International Journal of Antimicrobial Agents10, 23\u201330.","DOI":"10.1016\/S0924-8579(98)00020-X"},{"key":"key\n\t\t\t\t20170411034239_R11","doi-asserted-by":"crossref","unstructured":"Visalli, M. A., Jacobs, M. R. & Applebaum, P. C. (1997). Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral \u03b2-lactams. Antimicrobial Agents and Chemotherapy41,2786\u2013 9","DOI":"10.1128\/AAC.41.12.2786"},{"key":"key\n\t\t\t\t20170411034239_R12","doi-asserted-by":"crossref","unstructured":"Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In-vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy41,101\u2013 6.","DOI":"10.1128\/AAC.41.1.101"},{"key":"key\n\t\t\t\t20170411034239_R13","unstructured":"National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA."},{"key":"key\n\t\t\t\t20170411034239_R14","doi-asserted-by":"crossref","unstructured":"Thomson, K. S. & Sanders, C. C. (1998). The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Journal of Antimicrobial Chemotherapy42,179\u2013 87.","DOI":"10.1093\/jac\/42.2.179"},{"key":"key\n\t\t\t\t20170411034239_R15","doi-asserted-by":"crossref","unstructured":"Thomson, K. S. & Sanders, C. C. (1994). Dissociated resistance among fluoroquinolones. Antimicrobial Agents and Chemotherapy38, 2095\u2013100.","DOI":"10.1128\/AAC.38.9.2095"},{"key":"key\n\t\t\t\t20170411034239_R16","doi-asserted-by":"crossref","unstructured":"Thomson, K. S., Moland, E. S. & Sanders, C. C. (1999). Activity of trovafloxacin against antibiotic-resistant pathogens. Infectious Diseases in Clinical Practice8, Suppl. 1, S7\u201316.","DOI":"10.1097\/00019048-199905001-00003"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/44\/5\/621\/13056943\/JAC445621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T08:24:19Z","timestamp":1583310259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/44.5.621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1999,11]]},"published-print":{"date-parts":[[1999,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/44.5.621","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}